The Tumor Models Immuno-Oncology Summit 2023

3D Ex vivo Patient Tissue Platform for Immuno-Oncology Drug Testing

Many immuno-oncology drugs fail in clinical trials, which is partly due to the lack of in vitro and in vivo models that sufficiently recapitulate the tumor microenvironment (TME).

To bridge this gap in translational model systems, a 3D ex vivo patient tissue platform was developed which uses 3D ex vivo tumor cultures, where tumor endogenous cells of the TME are preserved. These TME components can affect tumor drug responses with potentially novel targets for drug development, making them a crucial component to be presented upon drug efficacy evaluations.

Download the Poster Now!